Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 5, 2006, Pages 931-936

  Ribes, Sandra ^a   Taberner, Ferran ^a   Domenech, Alejandro ^a   Cabellos, Carmen ^a   Tubau, Fe ^a   Liñares, Josefina ^a   Viladrich, Pedro Fernández ^a   Gudiol, Francesc ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cephalosporins; Pneumococcal meningitis; Resistance; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; CEPHALOSPORIN; FOSFOMYCIN; VANCOMYCIN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CEREBROSPINAL FLUID; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; EXPERIMENTAL INFECTION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; SINGLE DRUG DOSE; STRAIN DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-BACTERIAL AGENTS; CEFTRIAXONE; CEPHALOSPORIN RESISTANCE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOSFOMYCIN; MENINGITIS, PNEUMOCOCCAL; MICROBIAL SENSITIVITY TESTS; RABBITS; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN;

EID: 33645806091     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl047     Document Type: Article

References (30)

1. Friedland IR, McCracken GH, Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331: 377-82.
2. American Academy of Pediatrics. Therapy for children with invasive pneumococcal infections. Pediatrics 1997; 99: 289-9.
3. Tunkel AR, Hartman BJ, Kaplan SL et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39: 1267-84.
4. Nau R, Kaye K, Sachdeva M et al. Rifampin for therapy of experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother 1994; 38: 1186-9.
5. Perrig M, Acosta F, Cottagnoud M et al. Efficacy of gatifloxacin alone and combined with cefepime against penicillin-resistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro. J Antimicrob Chemother 2001; 47: 701-4.
6. Martinez-Lacasa J, Cabellos C, Martos A et al. Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J Antimicrob Chemother 2002; 49: 507-13.
7. Domenech A, Cabellos C, Ribes S et al. Experimental study of clinafloxacin alone and in combination in the treatment of ciprofloxacin-susceptible and -resistant pneumococcal meningitis. Microb Drug Resist 2003; 9 Suppl 1: S53-9.
8. Hendlin D, Stapley EO, Jackson M et al. Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science 1969; 166: 122-3.
9. Sicilia T, Estevez E, Rodriguez A. Fosfomycin penetration into the cerebrospinal fluid of patients with bacterial meningitis. Chemotherapy 1981; 27: 405-13.
10. Banon Arias R, Garcia Lopez M, Pinedo Sanchez A. Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae. J Chemother 2001; 13: 535-40.
11. Pfausler B, Spiss H, Dittrich P et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 2004; 53: 848-52.
12. Stahl JP, Croize J, Bru JP et al. Diffusion of fosfomycin into the cerebrospinal fluid in purulent meningitis. Presse Med 1984; 13: 2693-5.
13. Guggenbichler JP, Menardi G, Hager J. Antimicrobial therapy of bacterial meningitis in premature- and newborn infants and shunt infections. In: Guggenbichler JP, ed. New Aspects for Treatment with Fosfomycin, New York: Springer, 1987: 41-57.
14. Nau R, Zysk G, Reinert RR et al. Activity of fosfomycin in a rabbit model of experimental pneumococcal meningitis. J Antimicrob Chemother 1995; 36: 997-1004.
15. Sloas MM, Barrett FF, Chesney PJ et al. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 1992; 11: 662-6.
16. McGee L, McDougal L, Zhou J et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol 2001; 39: 2565-71.
17. Andrews JM, Baquero F, Beltran JM et al. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 1983; 12: 357-61.
18. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Villanova, PA, USA, 2000.
19. Eliopoulos GM, Moellering RC, Jr. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine, 4th edn. Baltimore: Williams & Wilkins Co., 1996; 330-6.
20. Dacey RG, Sande MA. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother 1974; 6: 437-41.
21. Ribes S, Domenech A, Cabellos C et al. Experimental meningitis due to a high-level cephalosporin-resistant strain of Streptococcus pneumoniae serotype 23F. Enferm Infecc Microbiol Clin 2003; 21: 329-33.
22. Cabellos C, Martinez-Lacasa J, Tubau F et al. Evaluation of combined ceftriaxone and dexamethasone therapy in experimental cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother 2000; 45: 315-20.
23. Sicilia T, Fadon A, Rodriguez A et al. Fosfomycin in pneumococcal meningitis. Chemotherapy 1977; 23 Suppl 1: 429-40.
24. Kuhnen E, Pfeifer G, Frenkel C. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection 1987; 15: 422-4.
25. Doit CP, Bonacorsi SP, Fremaux AJ et al. In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis. Antimicrob Agents Chemother 1994; 38: 2655-9.
26. Ribes S, Taberner F, Domenech A et al. Evaluation of ceftriaxone, vancomycin and rifampicin alone and combined in an experimental model of meningitis caused by highly cephalosporin-resistant Streptococcus pneumoniae ATCC 51916. J Antimicrob Chemother 2005; 56: 979-82.
27. Barakett V, Lesage D, Delisle F et al. Synergy of cefotaxime and fosfomycin against penicillin-resistant pneumococci. J Antimicrob Chemother 1993; 31: 105-9.
28. Cassinat B, Nicolas MH. Comparison of antibiotic combinations against penicillin-resistant pneumococci. J Antimicrob Chemother 1994; 34: 785-90.
29. Chavanet P, Beloeil H, Pechinot A et al. In vivo activity and pharmacodynamics of cefotaxime or ceftriaxone in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995; 39: 1736-43.
30. Tubau F, Cabellos C, Liñares J. Lack of correlation between in vitro and in vivo studies of combinations of rifampin plus vancomycin or beta-lactam antibiotics against Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 1573-4.